## Akihisa Imagawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4413051/publications.pdf

Version: 2024-02-01

90 papers

3,127 citations

236925 25 h-index 53 g-index

99 all docs 99 docs citations 99 times ranked 2287 citing authors

#	Article	IF	CITATIONS
1	Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design. Diabetology International, 2022, 13, 288-294.	1.4	4
2	Research following genomeâ€wide association study focuses on the multifaceted nature of Src kinaseâ€associated phosphoprotein 2 in type 1 diabetes. Journal of Diabetes Investigation, 2022, 13, 611-613.	2.4	0
3	Type $1$ diabetes related to immune checkpoint inhibitors. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101657.	4.7	8
4	Decreased cognitive function is associated with preceding severe hypoglycemia and impaired blood glucose control in the elderly individuals with type 1 diabetes. Diabetology International, 2022, 13, 679-686.	1.4	5
5	Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics. Scientific Reports, 2022, 12, .	3.3	O
6	Two types of fulminant typeÂ1 diabetes mellitus: Immune checkpoint inhibitorâ€related and conventional. Journal of Diabetes Investigation, 2021, 12, 917-919.	2.4	4
7	Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2). Advances in Therapy, 2021, 38, 1514-1535.	2.9	1
8	Characterization of salivary microbiota in elderly patients with type 2 diabetes mellitus: a matched caseâ€"control study. Clinical Oral Investigations, 2021, , 1.	3.0	14
9	Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Anticancer Research, 2021, 41, 5137-5145.	1.1	6
10	Fulminant type 1 diabetes patients display high frequencies of IGRP-specific type 1 CD8+ T cells. Clinical Immunology, 2021, 233, 108893.	3.2	1
11	Graves' disease and mental disorders. Journal of Clinical and Translational Endocrinology, 2020, 19, 100207.	1.4	19
12	Prediction of bortezomib-induced peripheral neuropathy with the Râ€"R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study. Leukemia and Lymphoma, 2020, 61, 707-713.	1.3	1
13	Pancreatic βâ€cells express major histocompatibility complex classÂll: Do diabetic βâ€cells have the capacity of antigenâ€presenting cells?. Journal of Diabetes Investigation, 2020, 11, 281-283.	2.4	2
14	Fulminant type 1 diabetes: recent research progress and future prospects. Diabetology International, 2020, 11, 336-341.	1.4	6
15	Distinct Phenotypes of Islet Antigen-Specific CD4+ T Cells Among the 3 Subtypes of Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3141-3151.	3.6	6
16	Fulminant type $1$ diabetes: nationwide effort to elucidate genetics, etiology, and pathogenesis since 2000. Diabetology International, 2020, $11$ , $342-343$ .	1.4	0
17	Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice. International Journal of Molecular Sciences, 2020, 21, 7495.	4.1	5
18	Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. International Journal of Cardiology, 2020, 313, 67-75.	1.7	19

#	Article	IF	CITATIONS
19	Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocrine Journal, 2019, 66, 581-586.	1.6	63
20	Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy. Internal Medicine, 2019, 58, 949-953.	0.7	4
21	Pathogenesis of fulminant typeÂ1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patientâ€derived induced pluripotent stem cells for future research. Journal of Diabetes Investigation, 2019, 10, 1158-1164.	2.4	30
22	T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors. Diabetes Care, 2019, 42, e116-e118.	8.6	67
23	Variants in the <i>BACH2</i> and <i>CLEC16A</i> gene might be associated with susceptibility to insulinâ€triggered typeÂ1 diabetes. Journal of Diabetes Investigation, 2019, 10, 1447-1453.	2.4	8
24	Case of a novel <i>PAX6</i> mutation with aniridia and insulinâ€dependent diabetes mellitus. Journal of Diabetes Investigation, 2019, 10, 552-553.	2.4	11
25	Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetology International, 2019, 10, 58-66.	1.4	65
26	Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in <i> CSAD/Inc-ITGB7-1 </i> > on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes. Diabetes, 2019, 68, 665-675.	0.6	31
27	"Preserved―glucagon secretion in fulminant type 1 diabetes. Journal of Diabetes Investigation, 2019, 10, 186-187.	2.4	4
28	Human pancreatic α―to β ell area ratio increases after type 2 diabetes onset. Journal of Diabetes Investigation, 2018, 9, 1270-1282.	2.4	17
29	Diffusion-weighted magnetic resonance imaging in the pancreas of fulminant type 1 diabetes. Diabetology International, 2018, 9, 257-265.	1.4	2
30	Impact of glycemic variability on the levels of endothelial progenitor cells in patients with type 1 diabetes. Diabetology International, 2018, 9, $113-120$ .	1.4	8
31	Predictors of postoperative bleeding after vitrectomy for vitreous hemorrhage in patients with diabetic retinopathy. Journal of Diabetes Investigation, 2018, 9, 940-945.	2.4	10
32	Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocrine Journal, 2018, 65, 521-526.	1.6	7
33	Characteristics of sleep–wake cycle and sleep duration in Japanese type 2 diabetes patients with visceral fat accumulation. Journal of Diabetes Investigation, 2018, 9, 63-68.	2.4	4
34	Complete loss of insulin secretion capacity in type 1A diabetes patients during longâ€term follow up. Journal of Diabetes Investigation, 2018, 9, 806-812.	2.4	10
35	Insulinâ€producing cells derived from †induced pluripotent stem cells' of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosisâ€related genes. Journal of Diabetes Investigation, 2018, 9, 481-493.	2.4	26
36	"Benifuuki―Extract Reduces Serum Levels of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Ligands Containing Apolipoprotein B: A Double-Blind Placebo-Controlled Randomized Trial. Nutrients, 2018, 10, 924.	4.1	7

#	Article	IF	CITATIONS
37	Factors associated with treatment satisfaction in patients with type 2 diabetes mellitus using oral glucose-lowering agents: a cross-sectional study in urban districts in Japan. Endocrine Journal, 2018, 65, 1001-1009.	1.6	9
38	Taurine improves glucose tolerance in STZ-induced insulin-deficient diabetic mice. Diabetology International, 2018, 9, 234-242.	1.4	9
39	A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2394-2400.	3.6	32
40	Clinical features of cases of seroconversion of anti-glutamic acid decarboxylase antibody during the clinical course of type 2 diabetes: a nationwide survey in Japan. Diabetology International, 2017, 8, 306-315.	1.4	1
41	Insulin degludec is associated with less frequent and milder hypoglycemia in insulin-deficient patients with type 1 diabetes compared with insulin glargine or detemir. Diabetology International, 2017, 8, 228-236.	1.4	5
42	Hyperinsulinemia and Insulin Receptor Gene Mutation in Nonobese Healthy Subjects in Japan. Journal of the Endocrine Society, 2017, 1, 1351-1361.	0.2	6
43	An Impaired Awareness of Hypoglycemia Improved After Vitamin B <sub>12</sub> Treatment in a Type 1 Diabetic Patient. Internal Medicine, 2017, 56, 1383-1385.	0.7	1
44	Multiple Gouty Tophi with Bone Erosion and Destruction: A Report of an Early-onset Case in an Obese Patient. Internal Medicine, 2017, 56, 1071-1077.	0.7	1
45	Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS ONE, 2016, 11, e0160576.	2.5	15
46	Risk factors for sudden death and cardiac arrest at the onset of fulminant type 1 diabetes mellitus. Diabetology International, 2016, 7, 281-288.	1.4	10
47	A case of glucocorticoid-induced diabetes in which the efficacy between sitagliptin and metformin was compared. Diabetology International, 2016, 7, 89-94.	1.4	4
48	Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. PLoS ONE, 2016, 11, e0155643.	2.5	18
49	Extent of weight reduction necessary for minimization of diabetes risk in Japanese men with visceral fat accumulation and glycated hemoglobin of 5.6–6.4%. Journal of Diabetes Investigation, 2015, 6, 553-559.	2.4	4
50	Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetology International, 2015, 6, 1-7.	1.4	44
51	Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovascular Diabetology, 2015, 14, 8.	6.8	17
52	Coefficient of variation of R-R interval closely correlates with glycemic variability assessed by continuous glucose monitoring in insulin-depleted patients with type 1 diabetes. Diabetes Research and Clinical Practice, 2015, 109, 397-403.	2.8	15
53	Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue. PLoS ONE, 2015, 10, e0144606.	2.5	4
54	Possible Contribution of Taurine to Distorted Glucagon Secretion in Intra-Islet Insulin Deficiency: A Metabolome Analysis Using a Novel α-Cell Model of Insulin-Deficient Diabetes. PLoS ONE, 2014, 9, e113254.	2.5	7

#	Article	IF	Citations
55	Diagnostic criteria for acuteâ€onset type 1 diabetes mellitus (2012): Report of the <scp>C</scp> ommittee of <scp>J</scp> apan <scp>D</scp> iabetes <scp>S</scp> ociety on the <scp>R</scp> esearch of <scp>F</scp> ulminant and <scp>A</scp> cuteâ€ <scp>o</scp> nset <scp>T</scp> ype 1 <scp>D</scp> iabetes <scp>M</scp> ellitus. Journal of Diabetes Investigation, 2014, 5, 115-118.	2.4	82
56	The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clinica Chimica Acta, 2014, 433, 184-189.	1.1	15
57	Glycated albumin as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring. Diabetology International, 2013, 4, 156-159.	1.4	15
58	Fulminant Type 1 Diabetes in Japan. , 2013, , 219-229.		1
59	Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovascular Diabetology, 2013, 12, 88.	6.8	15
60	Low gene expression levels of activating receptors of natural killer cells (NKG2E and CD94) in patients with fulminant type 1 diabetes. Immunology Letters, 2013, 156, 149-155.	2.5	12
61	Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012). Diabetology International, 2013, 4, 221-225.	1.4	13
62	Fulminant Type 1 Diabetes Mellitus. Advances in Experimental Medicine and Biology, 2013, 771, 20-23.	1.6	20
63	High Frequency of HLA B62 in Fulminant Type 1 Diabetes with the Drug-Induced Hypersensitivity Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2277-E2281.	3.6	32
64	Glycated Albumin to Glycated Hemoglobin Ratio is a Sensitive Indicator of Blood Glucose Variability in Patients with Fulminant Type 1 Diabetes. Internal Medicine, 2012, 51, 1315-1321.	0.7	35
65	Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodies. Journal of Diabetes Investigation, 2012, 3, 62-69.	2.4	63
66	Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012). Diabetology International, 2012, 3, 179-183.	1,4	20
67	Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovascular Diabetology, 2012, 11, 107.	6.8	51
68	Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acuteâ€onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Journal of Diabetes Investigation, 2012, 3, 536-539.	2.4	187
69	A case of long-standing autoimmune type $1$ diabetes with common variable immunodeficiency. Diabetology International, $2012, 3, 50-53$ .	1.4	2
70	Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes. Immunology Letters, 2011, 139, 80-86.	2.5	25
71	Predictors of deterioration of glucose tolerance and effects of lifestyle intervention aimed at reducing visceral fat in normal glucose tolerance subjects with abdominal obesity. Journal of Diabetes Investigation, 2011, 2, 218-224.	2.4	4
72	Clinical features of Japanese type 2 diabetics with insulinogenic index in normal range after treatment of glucotoxicity. Diabetology International, 2011, 2, 208-213.	1.4	0

#	Article	IF	CITATIONS
73	Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovascular Diabetology, 2011, 10, 109.	6.8	74
74	Fulminant type 1 diabetes—an important subtype in East Asia. Diabetes/Metabolism Research and Reviews, 2011, 27, 959-964.	4.0	90
75	Type 1 Diabetes and Interferon Therapy. Diabetes Care, 2011, 34, 2084-2089.	8.6	59
76	Expression of Toll-like Receptors in the Pancreas of Recent-onset Fulminant Type 1 Diabetes. Endocrine Journal, 2010, 57, 211-219.	1.6	76
77	Serum glycated albumin to haemoglobin A <sub>1C</sub> ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Annals of Clinical Biochemistry, 2010, 47, 313-317.	1.6	38
78	Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. Journal of Diabetes Investigation, 2010, 1, 283-285.	2.4	15
79	A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Research and Clinical Practice, 2008, 79, e8-e9.	2.8	49
80	Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Research and Clinical Practice, 2008, 82, 233-237.	2.8	21
81	Differences in the Contribution of the CTLA4 Gene to Susceptibility to Fulminant and Type 1A Diabetes in Japanese Patients. Diabetes Care, 2008, 31, 1608-1610.	8.6	35
82	Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Annals of Medicine, 2008, 40, 395-400.	3.8	15
83	Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 36-45.	2.8	178
84	Fulminant Type 1 Diabetes Mellitus. Endocrine Journal, 2006, 53, 577-584.	1.6	33
85	Pathogenesis of Fulminant Type 1 Diabetes. Review of Diabetic Studies, 2006, 3, 169-169.	1.3	57
86	Fulminant type 1 diabetes Warning to ER physicians. Journal of the Japanese Society of Intensive Care Medicine, 2005, 12, 1-2.	0.0	1
87	Fulminant Type 1 Diabetes. Diabetes Care, 2003, 26, 2345-2352.	8.6	278
88	Pancreatic Biopsy as a Procedure for Detecting In Situ Autoimmune Phenomena in Type 1 Diabetes. Diabetes, 2001, 50, 1269-1273.	0.6	151
89	A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence. Annals of Medicine, 2000, 32, 539-543.	3.8	62
90	A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies. New England Journal of Medicine, 2000, 342, 301-307.	27.0	614